We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Urology

Journal Scan / Research · March 21, 2018

Degarelix in Prolonging the Off-Treatment Interval in Men With Localized Prostate Cancer Receiving Intermittent ADT for Biochemical Recurrence Following Radical Local Therapy

The Journal of Urology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Journal of Urology
A Phase II, Randomized, Multicentre Study Comparing 10 Months Versus 4 Months of Degarelix (Firmagon®) Therapy in Prolonging the Off Treatment Interval in Men With Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence Following Radical Local Therapy
J Urol 2018 Mar 10;[EPub Ahead of Print], L Klotz, A Loblaw, R Siemens, P Ouellette, A Kapoor, M Kebabdjian, L Zhang, F Saad

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading